Diagnostics & IVD
Assays, point-of-care testing, sequencing and lab instruments. 7 companies listed.
Cleveland Diagnostics develops blood tests that read structural changes in cancer-related proteins. Its IsoPSA test helps urologists decide whether to biopsy men with elevated PSA.
Develops blood-based cancer screening tests built on cell-free DNA methylation and machine learning. SimpleScreen CRC is its first FDA-approved product; listed on Nasdaq as FRNM in July 2026.
Develops blood tests that quantify liver function from cholate clearance to stage liver disease and guide varices screening. Runs its own CLIA laboratory in Colorado.
Building real time 3D ultrasound systems meant to replace 2D imaging for procedures such as vascular access and central line placement.
Builds robotic microscopes and vision guided scanning systems for cancer diagnostics and digital pathology.
Built Sight OLO, a benchtop analyzer that runs a complete blood count from a small blood sample in minutes. The company laid off its remaining staff in April 2026.
Builds Aletta, an autonomous robotic blood-draw device that images the vein, inserts the needle and collects the sample. CE-marked in Europe; FDA granted De Novo authorization in August 2026.
New clearances, funding rounds and regulatory moves for device founders. No noise, no login.
You're in. The next morning brief lands in your inbox.